GSK Spies Pfizer Challenge With $2.1bn Vaccine Company Acquisition

First Vaccine M&A Deal For Departing Barron

GSK vaccines
GSK has a blockbuster in Shingrix, but needs to invest more widely to retain its leading status in vaccines. • Source: Shutterstock

More from Business

More from Scrip